Effect of different accessory devices on the dose delivered from pressurised metred-dose inhalers.

Szczegóły
Abstrakt

Tytuł:: Effect of different accessory devices on the dose delivered from pressurised metred-dose inhalers.
Autorzy:: Nicola M; Clinical Pharmacy Department, Faculty of Pharmacy, Beni-Suef University, Beni-Suef, Egypt.
Hussein RRS; Clinical Pharmacy Department, Faculty of Pharmacy, Beni-Suef University, Beni-Suef, Egypt.
Soliman YMA; Department of Chest Diseases, Faculty of Medicine, Cairo University, Giza, Egypt.
Abdelrahim M; Clinical Pharmacy Department, Faculty of Pharmacy, Beni-Suef University, Beni-Suef, Egypt.
Źródło:: International journal of clinical practice [Int J Clin Pract] 2021 Jun; Vol. 75 (6), pp. e14157. Date of Electronic Publication: 2021 Mar 30.
Typ publikacji:: Journal Article
Język:: English
Imprint Name(s):: Publication: 2022- : Mumbai : Hindawi
Original Publication: Esher [England] ; Bronxville, N.Y. : Medicom International, c1997-
MeSH Terms:: Albuterol*
Nebulizers and Vaporizers*
Administration, Inhalation ; Bronchodilator Agents ; Equipment Design ; Inhalation Spacers ; Metered Dose Inhalers
References:: Nicola M, Elberry A, Sayed O, Hussein R, Saeed H, Abdelrahim M. The impact of adding a training device to familiar counselling on inhalation technique and pulmonary function of asthmatics. Adv Ther. 2018;35:1049-1058.
Nicola M, Elberry AA, Sayed OM, Hussein RRS, Abdelrahim MEA. Effect of DPI's training-device on inhalation technique and clinical efficacy in asthmatics. Beni-Suef Univ J Basic Appl Sci. 2018;7:178-183.
Elgendy MO, Abdelrahim ME, Eldin RS. Potential benefit of repeated dry powder inhaler’s inhalation technique counseling on asthmatic patients. Pulm Ther. 2015;1:91-101.
Harb HS, Laz NI, Rabea H, Abdelrahim MEA. First-time handling of different inhalers by chronic obstructive lung disease patients. Exp Lung Res. 2020;46:258-269.
Willemse BW, Toelle BG, Li J, Shah S, Peat JK. Use of a paper disposable cup as a spacer is effective for the first-aid management of asthma. Respir Med. 2003;97:86-89.
Saeed H, Salem HF, Rabea H, Abdelrahim MEA. Effect of human error, inhalation flow, and inhalation volume on dose delivery from Ellipta® dry-powder inhaler. J Pharm Innov. 2019;14:239-244.
Elgendy MO, Abdelrahim ME, Eldin RS. Potential benefit of repeated MDI inhalation technique counselling for patients with asthma. Eur J Hosp Pharm. 2015;22:318-322.
Abdelrahim ME, Assi KH, Chrystyn H. Relative bioavailability of terbutaline to the lung following inhalation, using urinary excretion. Br J Clin Pharmacol. 2011;71:608-610.
Moustafa IOF, Ali M-A, Al Hallag M, et al. Lung deposition and systemic bioavailability of different aerosol devices with and without humidification in mechanically ventilated patients. Heart Lung. 2017;46:464-467.
Moustafa IOF, ElHansy MHE, Al Hallag M, et al. Clinical outcome associated with the use of different inhalation method with and without humidification in asthmatic mechanically ventilated patients. Pulm Pharmacol Ther. 2017;45:40-46.
McFadden E Jr. Improper patient techniques with metered dose inhalers: clinical consequences and solutions to misuse. J Allergy Clin Immunol. 1995;96:278-283.
Dolovich MB, Ahrens RC, Hess DR, et al. Device selection and outcomes of aerosol therapy: evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest. 2005;127:335-371.
Kwok PCL, Collins R, Chan H-K. Effect of spacers on the electrostatic charge properties of metered dose inhaler aerosols. J Aerosol Sci. 2006;37:1671-1682.
Rau JL. Practical problems with aerosol therapy in COPD. Respir Care. 2006;51:158-172.
Saeed H, Abdelrahim MEA, Rabea H, Salem HF, et al. Evaluation of disposable and traditional accessory devices for use with a pressurized metered-dose inhaler. Respir Care. 2020;65:06835.
Nicola M, Soliman YMA, Hussein R, Saeed H, Abdelrahim M. Comparison between traditional and non-traditional Add-on devices used with pressurized metered-dose inhalers. Eur Respir J Open Res. 2020;6:00073-2020.
Rahmatalla MF, Zuberbuhler PC, Lange CF, Finlay WH. In vitro effect of a holding chamber on the mouth-throat deposition of QVAR®(hydrofluoroalkane-beclomethasone dipropionate). J Aerosol Med. 2002;15:379-385.
Anderson G, Johnson N, Mulgirigama A, et al. Use of spacers for patients treated with pressurized metered dose inhalers: focus on the VENTOLIN™ Mini Spacer. Expert Opin Drug Deliv. 2018;15:419-430.
Lipworth B, Clark D. Early lung absorption profile of non-CFC salbutamol via small and large volume plastic spacer devices. Br J Clin Pharmacol. 1998;46:45-48.
Walsh J, Bickmann D, Breitkreutz J, Chariot-Goulet M. Delivery devices for the administration of paediatric formulations: overview of current practice, challenges and recent developments. Int J Pharm. 2011;415:221-231.
Mitchell JP, Coppolo DP, Nagel MW. Electrostatics and inhaled medications: influence on delivery via pressurized metered-dose inhalers and add-on devices. Respir Care. 2007;52:283-300.
Mitchell JP, Nagel MW. Valved holding chambers (VHCs) for use with pressurised metered-dose inhalers (pMDIs): a review of causes of inconsistent medication delivery. Prim Care Respir J. 2007;16:207-214.
Nikander K, Nicholls C, Denyer J, Pritchard J. The evolution of spacers and valved holding chambers. J Aerosol Med Pulm Drug Deliv. 2014;27:S-4-S-23.
Ditcham W, Murdzoska J, Zhang G, et al. Lung deposition of 99mTc-radiolabeled albuterol delivered through a pressurized metered dose inhaler and spacer with facemask or mouthpiece in children with asthma. J Aerosol Med Pulm Drug Deliv. 2014;27:S-63-S-75.
Nikander K, Berg E, Smaldone GC. Jet nebulizers versus pressurized metered dose inhalers with valved holding chambers: effects of the facemask on aerosol delivery. J Aerosol Med. 2007;20:S46-S58.
Vincken W, Levy ML, Scullion J, et al. Spacer devices for inhaled therapy: why use them, and how? ERJ Open Res. 2018;4:00065-2018.
Sheth P, Bertsch MD, Knapp CL, Myrdal PB. In vitro evaluation of nonconventional accessory devices for pressurized metered-dose inhalers. Ann Allergy Asthma Immunol. 2014;113:55-62.
Zar HJ, Levin ME. Challenges in treating pediatric asthma in developing countries. Pediatr Drugs. 2012;14:353-359.
Asmus MJ, Coowanitwong I, Kwon SH, Khorsand N, Hochhaus G. In vitro performance of two common valved holding chambers with a chlorofluorocarbon-free beclomethasone metered-dose inhaler. Pharmacotherapy. 2003;23:1538-1544.
Kissoon N, Teelucksingh S, Blake KV, Kesser B, Murphy SP, Geller D. Plastic bottles as spacers for a pressurized metered-dose inhaler: in vitro characteristics. The West Indian Med J. 2001;50:189-193.
Zar HJ, Brown G, Donson H, Brathwaite N, Mann MD, Weinberg EG. Home-made spacers for bronchodilator therapy in children with acute asthma: a randomised trial. Lancet. 1999;354:979-982.
Hindle M, Chrystyn H. Determination of the relative bioavailability of salbutamol to the lung following inhalation [see comments]. Br J Clin Pharmacol. 1992;34:311-315.
Silkstone V, Corlett S, Chrystyn H. Determination of the relative bioavailability of salbutamol to the lungs and systemic circulation following nebulization. Br J Clin Pharmacol. 2002;54:115-119.
Abdelrahman MM. Solid-phase extraction and HPLC-DAD for determination of salbutamol in urine samples. Anal Chem Lett. 2018;8:35-45.
Vincken W, Levy ML, Scullion J, Usmani OS, Dekhuijzen PNR, Corrigan CJ. Spacer devices for inhaled therapy: why use them, and how? ERJ Open Res. 2018;4:00065-2018.
De Backer W, Devolder A, Poli G, et al. Lung deposition of BDP/formoterol HFA pMDI in healthy volunteers, asthmatic, and COPD patients. J Aerosol Med Pulm Drug Deliv. 2010;23:137-148.
Mallol J, Aguirre V, Rhem R, Rodriguez J, Dolovich M. Therapeutic equivalence of three metered-dose inhalers containing salbutamol (Albuterol) in protecting against methacholine-induced bronchoconstriction in children with asthma. Pediatr Pulmonol. 2001;32:447-452.
Tomlinson H, Corlett S, Chrystyn H. Dose-response relationship and reproducibility of urinary salbutamol excretion during the first 30 min after an inhalation. Br J Clin Pharmacol. 2003;56:225-227.
Janssens HM, Devadason SG, Hop WCJ, LeSouëf PN, De Jongste JC, Tiddens HA. Variability of aerosol delivery via spacer devices in young asthmatic children in daily life. Eur Respir J. 1999;13:787-791.
Kenyon C, Thorsson L, Borgström L, Newman SP. The effects of static charge in spacer devices on glucocorticosteroid aerosol deposition in asthmatic patients. Eur Respir J. 1998;11:606-610.
Janssens H, Tiddens H. Facemasks and aerosol delivery by metered dose inhaler-valved holding chamber in young children: a tight seal makes the difference. J Aerosol Med. 2007;20:S59-S65.
Morton R, Mitchell J. Design of facemasks for delivery of aerosol-based medication via pressurized metered dose inhaler with valved holding chamber: key issues that affect performance. J Aerosol Med. 2007;20:S29-S45.
Boshra MS, Almeldien AG, Eldin RS, et al. Inhaled salbutamol from aerolizer and diskus at different inhalation flows, inhalation volume and number of inhalations in both healthy subjects and COPD patients. Exp Lung Res. 2019;45:84-91.
Ali AMA, Abdelrahim MEA. Modeling and optimization of terbutaline emitted from a dry powder inhaler and influence on systemic bioavailability using data mining technology. J Pharm Innov. 2014;9:38-47.
Chrystyn H. Methods to identify drug deposition in the lungs following inhalation. Br J Clin Pharmacol. 2001;51:289.
Substance Nomenclature:: 0 (Bronchodilator Agents)
QF8SVZ843E (Albuterol)
Entry Date(s):: Date Created: 20210325 Date Completed: 20210518 Latest Revision: 20210518
Update Code:: 20240105
DOI:: 10.1111/ijcp.14157
PMID:: 33763954
: Czasopismo naukowe

Full Text Finder

Introductions: Improved aerosol delivery of bronchodilators to chronic obstructive pulmonary disease (COPD) subjects is a cornerstone in the treatment approach. Drug delivery and response are improved with the use of accessory devices [spacers and valved holding chambers (VHCs)] with metred-dose inhalers (pMDIs). However, different accessory devices are available in the market with different properties that could affect aerosol delivery. Thus, this study aimed to assess the relative lung deposition and systemic bioavailability and compare bronchodilator response of salbutamol delivered using different accessory devices attached to pMDIs.
Methods: Twelve healthy subjects and twelve COPD subjects inhaled 300 μg salbutamol (3 pMDI puffs) using five different accessory devices with either masks or mouthpieces (Able, Aerochamber plus flow Vu, Dolphin chamber, Tipshaler spacer, and modified Drink bottle spacer). Urine samples were collected thirty minutes post-dosing and cumulatively for the next twenty-four hours, to determine and compare the relative lung deposition [0-0.5 hour excretion of urinary salbutamol (USAL0.5)] and systemic bioavailability [0.5-24 hours excretion of urinary salbutamol (USAL24)] of salbutamol from the selected accessory devices. Also, the difference between pre and post-inhalation forced expiratory volume in one second (ΔFEV 1 %) of predicted was determined for each accessory device.
Results: Urinary excretion of salbutamol (both USAL0.5 and USAL24 samples) in COPD subjects was significantly (P < .05) lower than in healthy subjects for all accessory devices. USAL0.5 and USAL24 in non-antistatic spacers (modified Drink bottle spacer and Dolphin chamber spacers) were significantly lower (P < .05) than that for antistatic spacers (Aerochamber plus flow Vu, Able and Tips-haler). No significant difference in USAL0.5 and USAL24 was observed between facemasks and mouthpieces. There was a significant difference (P < .05) in ΔFEV 1 % of predicted values between COPD subjects and healthy subjects. However, within the COPD group and the healthy group there was no significant difference in ΔFEV 1 % of predicted values between all accessory devices or between with mouthpiece or with a mask.
Conclusions: COPD subjects had lower aerosol delivered compared with healthy subjects. Anti-static accessory devices delivered a higher amount of aerosol compared with non-antistatic accessory devices. Even though the presence of a significant difference in aerosol delivery between non-antistatic and antistatic accessory devices no significant difference was found in the ΔFEV 1 % between all accessory devices.
(© 2021 John Wiley & Sons Ltd.)

Informacja